Berlex Foundation Seeks Workshop Applicants

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

DUMONT, NJ--The Berlex On-cology Foundation is seeking applicants for two workshops: Epidemiology and Clinical Trial Design, to be held August 23-29, 1996, in Brewster, Mass, and The Clinical Pharmacology of Anticancer Drugs, which will take place October 4-8, 1996, in Leesburg, Va.

DUMONT, NJ--The Berlex On-cology Foundation is seeking applicantsfor two workshops: Epidemiology and Clinical Trial Design, tobe held August 23-29, 1996, in Brewster, Mass, and The ClinicalPharmacology of Anticancer Drugs, which will take place October4-8, 1996, in Leesburg, Va.

Aimed at young investigators interested in cancer research, theinteractive workshops offer ample opportunity for one-on-one interfacingwith the faculty, as well as peer-to-peer networking.

The awards cover travel expenses, lodging, meals, course syllabus,and textbooks. The application deadlines are May 30, 1996, forthe epidemiology workshop, and June 30, 1996, for the anticancerdrugs course. Twenty scholars will be selected for each program.

All applicants must be currently enrolled in an accredited oncologytraining program and should possess a demonstrated interest incancer research. Applicants must supply a current curriculum vitae,letter of recommendation from the department chairman, and a one-pageletter describing the applicant's purpose in attending the program.

For more information, contact Svetlana Lisanti, Berlex OncologyFoundation, 80 W. Madison Ave., Dumont, NJ 07628, or telephone201-385-0006.

Recent Videos
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
3 experts in this video
6 experts are featured in this series.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
6 experts are featured in this series.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Related Content